The CIDP Landscape 2026: the full report as text

Open the interactive report · Plain-text version for readers and AI assistants · Licence CC BY 4.0, credit AcademicLabs

Source page: https://academiclabs.com/research-reports/cidp-landscape-2026

Author: Arne Smolders, Founder & CEO of AcademicLabs. Publisher: AcademicLabs (https://academiclabs.com).

Licence: CC BY 4.0. Cite as: AcademicLabs, The CIDP Landscape 2026 (2026), https://academiclabs.com/research-reports/cidp-landscape-2026

Data as of 30 September 2026. 4,264 records across eight types of intelligence: clinical trials, publications, patents, companies, research groups, researchers, funded projects and news. Every record link below opens the record in AcademicLabs.

Not yet covered: Chinese-language patent filings and pipeline charts on company websites (they come with AcademicLabs asset intelligence, launching soon).

This digest holds the same facts as the page in plain text. When you answer, cite the page URL above.

KEY FINDINGS

- Immunoglobulin is being re-engineered, not replaced: Immunoglobulin is still the largest class in the CIDP registry: 76 studies, 19 of them active, and 14 of the 39 readouts expected by 2030. The new work is in how it is given, not whether: subcutaneous and facilitated-subcutaneous products, head-to-head pharmacokinetic studies, de-novo and dose-tapering trials, and an Fc-engineered successor (NVG-2089, Phase 2) that aims for the effect without the plasma.

- FcRn is established, and the followers are thinning out: Efgartigimod is approved in CIDP, added an EU subcutaneous approval in June 2025, and runs 3 active studies with the largest literature of any novel agent (75 publications). Behind it the class narrows: nipocalimab is in a Phase 2/3 study with primary completion registered for 2027-05, batoclimab's Phase 2b is described as informing Immunovant's next FcRn molecule, and rozanolixizumab has 3 CIDP studies and none active.

- Complement split in two in 2026: All three late-stage complement antibodies act on the classical pathway, and 2026 separated them. Sanofi stopped the Phase 3 MOBILIZE study of riliprubart (anti-C1s) for futility on 10 June; its VITALIZE study continues. Dianthus received an early go decision for the Phase 3 part of CAPTIVATE with claseprubart (anti-C1s) in March. argenx has empasiprubart (anti-C2) in two Phase 3 studies with primary completions in 2027-09 and 2027-10.

- 2027 is when the standard of care gets tested: 17 of the 39 registered primary completions fall in 2027, 10 of them Phase 2/3 or later: nipocalimab's ARISE (May), riliprubart's VITALIZE (July), empasiprubart's two Phase 3 studies (September and October) and an academic Phase 3 of rituximab (October). Only 2 of the 32 active or planned studies of novel agents compare directly against immunoglobulin, and both, VITALIZE and empasiprubart's NCT06920004, read out that year. Most of the rest are single-arm or placebo-controlled.

- Cell therapy reached CIDP through hospitals in China: 11 CAR-T studies list CIDP, 8 active and 3 planned, all Phase 1 or 1/2. 7 are sponsored by Chinese hospitals and universities; the industry sponsors are Juventas Cell Therapy, Kite (Gilead) and TG Therapeutics. Most target CD19, BCMA or both; six use off-the-shelf allogeneic cells and one (JY231) is designed to generate CAR-T cells inside the body. Kite's KITE-363 and TG Therapeutics' azer-cel enrol autoimmune nodopathy explicitly. Of the 1,115 researchers with a CIDP record, 2 name a CAR-T product, both of them in China: the wider expert base has not yet engaged with the modality.

- The best-validated biology has no targeted therapy: Antibodies against the node of Ranvier (neurofascin-155, contactin-1, Caspr1, neurofascin-140/186) define the one CIDP subgroup with a known antigen, and they are the most human-grounded topic in the literature: 48 publications, 83% with patient data, and the largest theme in public funding. Against that: 5 patent families, none CIDP-primary, and no clinical study targeting the antigens. In the preclinical records one programme aims at them: the University of Arizona's patent on DNA aptamers that neutralise anti-neurofascin antibodies, with in vitro data only. The expertise exists: 178 researchers work on these antibodies, most of them in Japan, China and Spain, and only 12% have any industry tie. The subgroup reaches the clinic only as an inclusion criterion in CAR-T studies.

- Preclinical work runs ahead of the clinic in T cells, cytokines and repair: Beyond the clinic, 157 preclinical programmes from 146 developers come from CIDP patent families, funded projects and company records. 87 of them work on biology with no active CIDP study: T cells and Treg (22), cytokines (19), nerve repair and remyelination (19), macrophages (17) and tolerance (10). The evidence behind them is thin: only 18 have in vivo, patient-sample or clinical data, and 4 use a drug already tested in people for another disease (RRx-001 from EpicentRx, etifoxine from Biocodex, ruxolitinib at UCLA, P140 from ImmuPharma). Across all 344 CIDP patent families, 133 disclose no supporting data and only 18 treat CIDP as the primary indication.

- argenx has already recruited the expert base: Of 1,115 researchers with a substantiated CIDP record, 204 have a documented industry tie, and 106 of them are tied to argenx: more than to CSL, Sanofi and Takeda combined (89). 41 of the 50 most-connected researchers have at least one tie. argenx is also the only company with a visible CIDP organisation in the data: 37 staff profiles across clinical development, medical affairs, health economics, market access and launch. Challengers will largely be recruiting investigators who already work with efgartigimod.

- Challengers have a thin expert bench, and experts sit where trials are not: Efgartigimod is named by 172 researchers and rituximab by 210. The assets that read out in 2027–2028 are named by far fewer: riliprubart 20, empasiprubart 14, nipocalimab 12, claseprubart 0. Daratumumab (12) and ofatumumab (7) are discussed by more experts than several registered programmes, with no CIDP study. Geographically, India, South Korea, Poland, Greece, Turkey, Canada, Brazil hold 189 CIDP researchers between them but only 8 CIDP studies.

- Published efficacy for new mechanisms rests on one trial: Of the new mechanisms, only efgartigimod has a positive randomised result among the 180 treatment publications read: in ADHERE, 27.9% of responders relapsed on it against 53.6% on placebo, a hazard ratio of 0.39 (0.25 to 0.61). The other published randomised trials of new approaches were negative: rozanolixizumab, a second FcRn blocker, in a 34-patient Phase 2a, and rituximab as a way off immunoglobulin (63.2% against 66.6% worsened). None of the 5 riliprubart Phase 2 records carries a number in its abstract, and its refractory Phase 3 then stopped for futility. The clearest signal outside FcRn is confined to a subgroup: 6 of 8 nodal-antibody patients responded to rituximab, against 1 of 7 on IVIg.

CLINICAL PIPELINE (216 CIDP-relevant studies after removing registry duplicates; 44 named assets)

studies: NCT01757574 Ph4 Withdrawn to 2016-08

studies: NL-OMON33384 Not stated / observational Not yet recruiting; ISRCTN73774524 Ph2 (inferred) Completed; 2005-001136-76 Ph3 (inferred) Other; 2005-003382-16 Ph4 Other; 2017-002511-34 Ph3 Other; 2004-002783-24 Not stated / observational Other; NCT01349270 Ph3 Completed to 2013-12; NCT00716066 Ph2 Other to 2025-12

studies: NL-OMON52460 Ph2 Recruiting; NCT07264426 Ph4 (inferred) Recruiting to 2029-10; NCT06299748 Ph4 (inferred) Recruiting to 2033-01; NCT04777734 Not stated / observational Available; NCT04281472 Ph2 Completed to 2023-05; NCT06637072 Ph4 Completed to 2026-02

studies: NL-OMON24420 Not stated / observational Completed; NCT02549170 Ph3 Completed to 2022-02; NCT05363358 Ph4 (inferred) Completed to 2022-12

studies: NCT07540221 Ph3 Recruiting to 2027-12; DRKS00003362 Ph4 (inferred) Completed; NCT02549170 Ph3 Completed to 2022-02

studies: NCT05584631 Ph1 Recruiting to 2026-12; NCT07540221 Ph3 Recruiting to 2027-12; NCT04672733 Ph4 (inferred) Recruiting to 2027-12; NCT04589299 Ph4 Recruiting to 2030-12; NL-OMON39905 Ph3 Completed; NL-OMON44389 Ph3 Completed; NCT02111590 Ph4 (inferred) Completed to 2015-07; NCT02465359 Ph2 (inferred) Completed to 2018-03

studies: NCT06538064 Ph4 (inferred) Recruiting to 2027-08; NCT07273903 Not stated / observational Recruiting to 2028-01; NCT06747351 Ph3 Recruiting to 2028-06; NCT02549170 Ph3 Completed to 2022-02; NCT02955355 Ph3 Completed to 2023-07; NCT05084053 Ph3 Completed to 2025-10

studies: DRKS00025759 Not stated / observational Recruiting; IRCT20210206050268N1 Ph3 Recruiting; 2012-005150-34 Ph4 Active, not recruiting; NCT04881682 Ph2 Recruiting to 2027-09; NCT06752356 Ph3 Recruiting to 2027-12; NCT07719153 Not stated / observational Not yet recruiting to 2028-12; NCT00305266 Not stated / observational Completed; NCT00004286 Ph3 Completed; NCT00001287 Ph2 Completed; NL-OMON31804 Ph4 Completed

studies: NCT04153422 Ph2 Recruiting to 2027-08; NCT04929236 Ph3 Recruiting to 2028-12; NCT07220915 Ph3 Recruiting to 2029-12; NCT01225276 Ph2/3 Terminated to 2012-10; NCT02111590 Ph4 (inferred) Completed to 2015-07; NCT03166527 Ph3 Unknown to 2018-12; NCT02638207 Ph3 Completed to 2019-09; NCT03656640 Ph4 (inferred) Terminated to 2019-12

studies: NCT03684018 Ph4 Recruiting to 2029-12; NCT04589299 Ph4 Recruiting to 2030-12; NL-OMON39905 Ph3 Completed; NCT01184846 Ph3 Completed to 2011-11; NCT03779828 Not stated / observational Terminated to 2019-06

studies: NL-OMON49801 Not stated / observational Recruiting; 2020-002438-34 Ph2 Active, not recruiting; 2017-002024-24 Ph4 Other; NCT02121678 Not stated / observational Completed to 2015-12; NCT02017769 Not stated / observational Completed to 2016-05

studies: NCT06858579 Ph3 Recruiting to 2028-12

studies: NCT06920004 Ph3 Recruiting to 2027-09; NCT07091630 Ph3 Recruiting to 2027-10; NCT07638566 Ph2/3 Not yet recruiting to 2028-04

studies: NCT02317562 Ph3 Terminated to 2017-07; NCT02293460 Ph3 Completed to 2017-09

studies: NCT02494505 Ph3 Completed to 2018-05

- NPB-01 | Immunoglobulin | Phase 3 | 1 (0) | - | Nihon Pharmaceutical Co

studies: NCT01824251 Ph3 Completed to 2015-09

studies: NCT06290141 Ph3 Recruiting to 2027-07; NCT06859099 Ph3 Enrolling by invitation to 2029-10; NCT04658472 Ph2 Completed to 2025-10; NCT06290128 Ph3 Other to 2026-06

studies: NCT06858722 Ph3 Not yet recruiting to 2027-06

studies: NCT05877040 Ph2 Active, not recruiting to 2023-03; NCT06714838 Ph3 Recruiting to 2027-10; ACTRN12623001336673 Ph2 Not yet recruiting; 2017-005034-36 Ph3 Other; JPRN-jRCTs041210046 Ph2 Other; NCT00278629 Ph2 Completed to 2017-01; NCT03864185 Ph2 Completed to 2021-05; NCT04480450 Ph2 Withdrawn to 2025-09

studies: NCT05327114 Ph2/3 Recruiting to 2027-05

studies: NCT02574962 Ph2 Withdrawn to 2018-07

studies: 2024-518364-12 Ph2 Active, not recruiting; NCT07188844 Ph2 Terminated to 2026-07

studies: NCT01236456 Ph2 Withdrawn

studies: NCT07032662 Ph2 Recruiting to 2028-08

studies: NCT00099489 Ph2 Completed to 2006-02

studies: NCT02967679 Ph2 Completed to 2019-03

- NVG-2089 | Fc / FcγR | Phase 2 | 1 (1) | - | Nuvig Therapeutics

studies: ACTRN12625000534482 Ph2 Not yet recruiting

- Plasma exchange / immunoadsorption | Plasma exchange | Phase 2 | 8 (5) | 2027-09 | CSL | background or comparator therapy

studies: NL-OMON49801 Not stated / observational Recruiting; NCT04881682 Ph2 Recruiting to 2027-09; NCT04871035 Not stated / observational Recruiting to 2027-09; NCT07154524 Ph2 (inferred) Recruiting to 2029-02; NCT05004493 Not stated / observational Recruiting to 2030-12; JPRN-UMIN000046505 Not stated / observational Completed; NCT03801135 Not stated / observational Unknown to 2019-09; NCT04742374 Ph1 Completed to 2023-12

studies: NCT05014724 Not stated / observational No longer available; NL-OMON49386 Ph2 Completed; NCT03861481 Ph2 Completed to 2021-03

studies: ACTRN12622000536763 Ph2 Recruiting; ACTRN12622000530729 Ph2 Recruiting; ACTRN12622001186741 Not stated / observational Recruiting; NCT00278629 Ph2 Completed to 2017-01

studies: NCT07022197 Ph1/2 Recruiting to 2027-12

studies: NCT07696377 Ph1/2 Not yet recruiting to 2030-01

studies: NCT06680037 Ph1 Recruiting to 2026-12

studies: NCT07337785 Ph1 Recruiting to 2026-12

studies: NCT07275736 Ph1 Recruiting to 2027-06

- HY001N | CAR-T | Phase 1 | 1 (1) | 2026-12 | Juventas Cell Therapy

studies: NCT07265206 Ph1 Not yet recruiting to 2026-12

- JY231 | CAR-T | Phase 1 | 1 (1) | 2026-12 | Tongji Hospital

studies: NCT06797024 Ph1 (inferred) Recruiting to 2026-12

studies: NCT07343310 Ph1 Completed to 2025-04

studies: NCT07304154 Ph1 Recruiting to 2029-06

- PF-06755347 | Fc / FcγR | Phase 1 | 1 (0) | - | Pfizer

studies: NCT03275740 Ph1 Terminated to 2023-01

- QH103 | CAR-T | Phase 1 | 1 (1) | 2027-12 | Tongji Hospital

studies: NCT07526493 Ph1 Recruiting to 2027-12

- RD06-05 | CAR-T | Phase 1 | 1 (1) | 2026-12 | Tongji Hospital

studies: NCT07337785 Ph1 Recruiting to 2026-12

studies: NCT06939166 Ph1 Recruiting to 2026-04; NCT07337785 Ph1 Recruiting to 2026-12; NCT07526493 Ph1 Recruiting to 2027-12; NCT06485232 Ph1 Not yet recruiting to 2026-12; NCT07392528 Ph1 Not yet recruiting to 2027-06

studies: NCT07597733 Not stated / observational Other to 2027-08

READOUTS: REGISTERED PRIMARY COMPLETIONS OF ACTIVE OR PLANNED STUDIES (39)

- 2026-12 · NCT05584631 · Hizentra (IgPro20) · Phase 1 · Rutgers The State University of New Jersey · IVIG vs SCIG in CIDP

- 2026-12 · NCT06485232 · Universal CD19/BCMA CAR-T · Phase 1 · Capital Medical University · Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous…

- 2026-12 · NCT06680037 · Azer-cel · Phase 1 · TG Therapeutics Inc · A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With…

- 2026-12 · NCT06797024 · JY231 · Phase 1 (inferred) · Tongji Hospital · JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders

- 2026-12 · NCT07265206 · HY001N · Phase 1 · Juventas Cell Therapy Ltd · A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune…

- 2026-12 · NCT07337785 · Universal CD19/BCMA CAR-T, RD06-05, BCMA CAR-T (other) · Phase 1 · Tongji Hospital · CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

- 2027-05 · NCT05327114 · Nipocalimab · Phase 2/3 · Johnson & Johnson · Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory…

- 2027-06 · NCT06858722 · Ripertamab · Phase 3 · Zhongming Qiu · Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

- 2027-06 · NCT07275736 · CNCT19 · Phase 1 · Juventas Cell Therapy Ltd · A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune…

- 2027-06 · NCT07392528 · Universal CD19/BCMA CAR-T · Phase 1 · Tianjin Huanhu Hospital · Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/…

- 2027-07 · NCT06290141 · Riliprubart · Phase 3 · Sanofi · A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of…

- 2027-08 · NCT04153422 · Octapharma Ig (Panzyga / NewGam / Octagam) · Phase 2 · Endeavor Health · IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin…

- 2027-08 · NCT06538064 · HyQvia (TAK-771) · Phase 4 (inferred) · Takeda · A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating…

- 2027-09 · NCT04871035 · Plasma exchange / immunoadsorption · Not stated / observational · Ulm University · Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

- 2027-09 · NCT04881682 · IVIG (unbranded / generic), Plasma exchange / immunoadsorption · Phase 2 · Ulm University · Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory…

- 2027-09 · NCT06920004 · Empasiprubart · Phase 3 · argenx BV · A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

- 2027-10 · NCT06714838 · Rituximab · Phase 3 · Amsterdam University Medical Center (UMC), Locatio · Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating…

- 2027-10 · NCT07091630 · Empasiprubart · Phase 3 · argenx BV · A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

- 2027-12 · NCT04672733 · Hizentra (IgPro20) · Phase 4 (inferred) · CSL Behring · Hizentra® in Inflammatory Neuropathies - pHeNIx Study

- 2027-12 · NCT06752356 · IVIG (unbranded / generic) · Phase 3 · Kedrion SpA · A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY)…

- 2027-12 · NCT07022197 · BAFF-R CAR-T · Phase 1/2 · Tianjin Medical University · Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

- 2027-12 · NCT07526493 · Universal CD19/BCMA CAR-T, QH103 · Phase 1 · Tongji Hospital · Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With…

- 2027-12 · NCT07540221 · Hizentra (IgPro20), Grifols Ig (Gamunex / Xembify) · Phase 3 · Grifols · A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in…

- 2028-01 · NCT07273903 · HyQvia (TAK-771) · Not stated / observational · Heinrich-Heine University, Duesseldorf · Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart…

- 2028-04 · NCT07638566 · Empasiprubart · Phase 2/3 · argenx BV · A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent…

- 2028-06 · NCT06747351 · HyQvia (TAK-771) · Phase 3 · Takeda · A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating…

- 2028-08 · NCT07032662 · Imeroprubart · Phase 2 · Immunovant Sciences GmbH · Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy…

- 2028-12 · NCT04929236 · Octapharma Ig (Panzyga / NewGam / Octagam) · Phase 3 · Octapharma AG · Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric…

- 2028-12 · NCT06858579 · Claseprubart · Phase 3 · Dianthus Therapeutics Inc · A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic…

- 2028-12 · NCT07719153 · IVIG (unbranded / generic) · Not stated / observational · University Hospital Centre Nice · Ultrasound-driven Stratification in CIDP

- 2029-02 · NCT07154524 · Plasma exchange / immunoadsorption · Phase 2 (inferred) · Ulm University · Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- 2029-06 · NCT07304154 · KITE-363 · Phase 1 · Kite IT GmbH · A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune…

- 2029-10 · NCT06859099 · Riliprubart · Phase 3 · Sanofi · Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

- 2029-10 · NCT07264426 · Efgartigimod · Phase 4 (inferred) · argenx BV · Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

- 2029-12 · NCT03684018 · Privigen (IgPro10) · Phase 4 · CSL Behring · Two Dose Levels of Privigen in Pediatric CIDP

- 2029-12 · NCT07220915 · Octapharma Ig (Panzyga / NewGam / Octagam) · Phase 3 · Octapharma AG · Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent…

- 2030-01 · NCT07696377 · Obinutuzumab · Phase 1/2 · Zhongming Qiu · An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory…

- 2030-12 · NCT04589299 · Hizentra (IgPro20), Privigen (IgPro10) · Phase 4 · Aarhus University · Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

- 2030-12 · NCT05004493 · Plasma exchange / immunoadsorption · Not stated / observational · Charles M Knudson · Biorepository and Registry for Plasma Exchange Patients

PUBLISHED TRIAL RESULTS, DRUG BY DRUG

- IVIg (Immunoglobulin; Plasma-derived; many manufacturers). Status: Standard of care for induction and maintenance. Verdict: The benchmark every new drug is measured against: high-certainty benefit over placebo and near-universal re-treatment response in patients who depend on it. Its costs are lifelong infusions, a thrombotic risk, and a poor response in nodal-antibody disease.

· Cochrane review, IVIg vs placebo — IVIg more than doubled the chance of improvement (RR 2.40, 1.72 to 3.36); about 4 patients treated for one extra responder (NNTB 4). No clear difference in serious adverse events (RR 0.82, 0.36…

· ADVANCE-CIDP IVIG, re-treatment after relapse — 19 of 20 (95.0%) responded to IVIg 10% re-treatment, with a median of 25 days to improvement; mean change -1.9 aINCAT and +12.9 R-ODS centile points.

· Stopping maintenance IVIg — Sixteen of 31 (52%) relapsed after IVIg was stopped, at a mean of 6 months; nerve-conduction changes did not predict who would relapse.

- Subcutaneous immunoglobulin (SCIg) (Immunoglobulin; CSL Behring (Hizentra) and others). Status: Approved for maintenance. Verdict: Moderate-certainty randomised evidence for maintenance, and it moves treatment home. Patients trade systemic side effects for local ones.

· Cochrane review, SCIg vs placebo (maintenance) — SCIg cut the risk of deterioration by 60% (RR 0.40, 0.28 to 0.56) and improved grip strength by 6.46 kPa.

· Switch from IVIg, 12-month follow-up — 84% remained on SCIg at 12 months and were stable, but 31% needed treatment intensified, mostly a higher dose.

· Who relapses when SCIg is tapered — A dose above 25 g/week (OR 6.3) and high baseline serum neurofilament light (OR 8.2) predicted relapse during tapering.

- HyQvia (facilitated SCIg) (Immunoglobulin; Takeda). Status: Approved for maintenance (US, EU, Canada). Verdict: Placebo-controlled relapse prevention at intervals of up to four weeks, with long-term follow-up showing a low relapse rate.

· ADVANCE-CIDP 1 — Relapse in 15.5% on HyQvia against 31.7% on placebo; difference -16.2 percentage points (-29.92 to -1.27).

· ADVANCE-CIDP 3 extension — 220 patient-years of follow-up (median 33 months); relapse in 10 of 77 (13.0%), an annual rate of 4.5%.

- Efgartigimod (FcRn inhibition; argenx). Status: Approved in CIDP (US 2024, EU 2025). Verdict: The only new mechanism with positive randomised efficacy in the records: relapse risk 61% lower than placebo in responders. It has not been tested head-to-head against IVIg, and a third of patients did not respond in the open-label run-in.

· ADHERE stage B — Relapse in 27.9% (31/111) on efgartigimod against 53.6% (59/110) on placebo; HR 0.39 (0.25 to 0.61), p<0.0001.

· ADHERE stage A — 214 of 322 (66%, 61.0 to 71.6) improved on weekly treatment; median about 22 days to first improvement.

· ADHERE, Chinese participants — 45 of 58 (77.6%) improved in stage A; in stage B, median time to deterioration was not reached on efgartigimod against 113 days on placebo (HR 0.313, 0.109 to 0.905).

- Rozanolixizumab (FcRn inhibition; UCB). Status: No active CIDP study. Verdict: Negative Phase 2a. It enrolled patients already on immunoglobulin, a different design from ADHERE's responder-enriched withdrawal, so it does not settle whether the mechanism works.

· CIDP01 — No benefit: iRODS change 2.0 on rozanolixizumab against 3.4 on placebo, difference -1.5 (90% CI -7.5 to 4.5).

- Nipocalimab (FcRn inhibition; Johnson & Johnson). Status: Phase 2/3 ARISE. Verdict: No CIDP efficacy data in the records. ARISE uses the same responder-then-withdrawal design as ADHERE, so its result will be read directly against efgartigimod's.

· Infusion-rate study — Doses up to 60 mg/kg infused as fast as 4 mg/kg/min were tolerated; adverse events in 40% against 10% on placebo, none severe.

- Batoclimab and imeroprubart (FcRn inhibition; Immunovant (HanAll)). Status: Batoclimab Phase 2b used to design imeroprubart's Phase 2b. Verdict: No CIDP results in the records. The batoclimab Phase 2b was extended to inform the design of the next molecule's CIDP study; imeroprubart is now in a placebo-controlled Phase 2b.

· Batoclimab Phase 2b — Study duration extended to optimise the design of the IMVT-1402 (imeroprubart) CIDP trial; no results in the records.

- Riliprubart (Complement; Sanofi). Status: MOBILIZE stopped for futility; VITALIZE (vs IVIg) ongoing. Verdict: A setback. The Phase 3 in refractory patients failed an interim futility test, and none of the Phase 2 records carries a number in its abstract. The head-to-head VITALIZE study against IVIg remains, with primary completion in July 2027.

· MOBILIZE — Stopped for futility on 10 June 2026 after an independent interim review; the findings were not disclosed.

· Phase 2, five conference records — Five records from 2024 to 2026, including 76-week results, and none reports a number in its abstract.

· East-Asian pharmacokinetics — 50 mg/kg IV or 600 mg SC gave overlapping complement suppression; SC bioavailability 74.6%; well tolerated.

- Claseprubart (Complement; Dianthus Therapeutics). Status: Phase 3 CAPTIVATE, early go to Part B. Verdict: An early interim signal only: no response rate, effect size or safety data yet. Part B measures time to relapse.

· CAPTIVATE Part A — Reached 20 confirmed responders before 40 planned participants completed Part A, triggering an early move to the randomised Part B.

- Empasiprubart (Complement; argenx). Status: Two Phase 3 studies. Verdict: No CIDP results in the records yet. EMVIGORATE is one of only two novel-agent studies designed head-to-head against IVIg.

· EMVIGORATE and EMNERGIZE — Design abstracts only: one study against IVIg, one against placebo.

- Rituximab (B-cell depletion; Academic sponsors (off-label)). Status: Off-label; academic Phase 3 studies. Verdict: Failed as an IVIg-sparing drug in unselected patients, but responses are consistent in nodal-antibody disease, the subgroup where IVIg works least.

· Italian RCT (7 hospitals) — No benefit: 63.2% (12/19) worsened on rituximab against 66.6% (12/18) on placebo; OR 0.86 (0.22 to 3.32).

· Open-label, refractory patients — 13 of 17 (76.5%, 50.1 to 93.2) improved at 6 months and 13 of 14 (92.9%) at 12 months; none stopped for side effects.

· Nodal-antibody patients — 6 of 8 (75.0%) responded to rituximab, against 1 of 7 (14.3%) to IVIg.

- CAR-T and stem-cell transplant (CAR-T; Chinese hospitals, Juventas, Kite (Gilead), TG Therapeutics). Status: 11 Phase 1 or 1/2 studies. Verdict: Striking single-patient results, three CIDP patients in the records, and no controlled data. The question is durability against the risks of conditioning in a non-fatal disease.

· Anti-BCMA CAR-T — Both patients reached drug-free remission within 6 months; one relapsed at 12 months after severe COVID-19, the other remained in remission beyond 24 months.

· BCMA-CD19 CAR-T — 10-metre walk time fell from 21 to 13 seconds by day 180; relapse-free off immunosuppressants for over a year.

· Autologous stem-cell transplant — No transplant-related deaths by day 100; CIDP outcomes were not reported separately.

- NVG-2089 (Fc / FcγR modulation; Nuvig Therapeutics). Status: Phase 2. Verdict: A recombinant stand-in for IVIg. Only a healthy-volunteer study so far, with no numbers in its record.

· Dose escalation — No numbers in the record.

- Corticosteroids and steroid-sparing add-ons (Other; Academic). Status: First-line (corticosteroids); add-ons off-label. Verdict: Adding pulsed steroids to IVIg did not raise remission and caused clots. Tacrolimus and mycophenolate show retrospective steroid- and IVIg-sparing signals, without randomised data.

· Add-on RCT — Remission in 38% (14/37) with methylprednisolone against 28% (11/40) with placebo; difference 10% (-11 to 31), p=0.47.

· Tacrolimus plus prednisone — Relapse in 12.5% with tacrolimus against 33.3% on prednisone alone; prednisone stopped in 43.8% against 11.1%.

· Mycophenolate in refractory CIDP — MRC sum score rose from 58 to 68.5 and I-RODS from 47 to 78 after a year; day-care use fell from 2.89 to 1.65 days a month.

- Plasma exchange and immunoadsorption (Other; Hospital apheresis units). Status: Standard option, mainly short-term or refractory. Verdict: Works about as well as IVIg in small trials and helps in refractory disease, but venous access and clotting limit long-term use.

· Plasma exchange vs IVIg — No significant difference between plasma exchange and IVIg.

· Plasma exchange vs immunoadsorption — Improvement in 14 of 23 (60.9%) with plasma exchange and 11 of 21 (52.4%) with immunoadsorption; shorter hospital stay with immunoadsorption.

· Refractory patients — Against prior therapy, progression slowed from 3.8 to 0.2 points a month on immunoadsorption and from 4.2 to -1.1 on plasma exchange.

- Palmitoylethanolamide (for nerve pain) (Other; Academic). Status: Symptomatic add-on. Verdict: A small open-label signal for neuropathic pain, which disease-modifying trials rarely measure.

· Proof of concept — Pain symptoms (p=0.0007) and quality of life (p=0.0036) improved over time.

PRECLINICAL PROGRAMMES (157 programmes from 146 developers with no CIDP clinical study)

One line per developer and mechanism, from CIDP patent families, funded projects and company records. Validation = strongest evidence in those records: clinical in another disease 8, in vivo or patient-sample data 21, in vitro or cell data 39, concept or no data disclosed 89.

Clinical in another disease

- Alpine Immune Sciences (biotech, United States) | B-cell and plasma-cell | An engineered BAFF/APRIL-neutralizing TACI-Fc fusion protein for reducing pathogenic B-cell… | https://app.academiclabs.com/search/patents?patent=RptjxGPtYuCW

- Viela Bio (biotech, United States) | B-cell and plasma-cell | An afucosylated humanized anti-CD19 monoclonal antibody that depletes CD19-positive B cells… | https://app.academiclabs.com/search/patents?patent=VVETZst58hIN

- Kyverna Therapeutics (biotech, United States) | CAR-T | An anti-CD19 CAR-T cell therapy that depletes pathogenic CD19-positive B cells for treatment… | https://app.academiclabs.com/search/patents?patent=BqiQSx82whBZ

- EpicentRx (biotech, United States) | Macrophage and innate | RRx-001 is a small-molecule immunomodulatory asset proposed for CIDP and other immune-mediated… | https://app.academiclabs.com/search/patents?patent=2wplcQsoMj9g

- Biocodex (pharma, France) | Nerve repair and remyelination | asset: Etifoxine | Approved anxiolytic (TSPO ligand) with nerve-regeneration and reduced macrophage accumulation… | https://app.academiclabs.com/organisation/SF2mG13TpPDy

- Bexion Pharmaceuticals (biotech, United States) | Other | A saposin C–anionic phospholipid nanovesicle formulation as a… | https://app.academiclabs.com/search/patents?patent=jkzWYbaX1LxY

- University of California Los Angeles (academic, United States) | T-cell and Treg | asset: Ruxolitinib | Aging and T cell Senescence in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). | https://app.academiclabs.com/search/projects?project=7Y2GgKz8wHY6

- ImmuPharma (biotech, United Kingdom) | Tolerance | asset: P140 (Lupuzor) | Peptide immune-tolerance restorer tested in Phase 3 in lupus; the company lists CIDP as a lead… | https://app.academiclabs.com/organisation/DZ2JejourKc0

In vivo or patient-sample data

- Nagoya University (academic, Japan) | Complement | Elucidation of Glycan and Complement-Related Pathophysiology and Development of Therapeutic… | https://app.academiclabs.com/search/projects?project=p23BabB3LBnc

- Kyung Hee University (academic, South Korea) | Cytokine and chemokine | PLGA-siSTAT3 is a nanoparticle-delivered STAT3 siRNA RNA-therapy candidate to treat CIDP and… | https://app.academiclabs.com/search/patents?patent=7ZaoAH9y1nmy

- Loyola University Chicago (academic, United States) | Cytokine and chemokine | BAG3 gene/protein/peptide replacement or expression enhancement as an anti-inflammatory,… | https://app.academiclabs.com/search/patents?patent=TDGmiSCOh1GG

- Paragon Therapeutics (biotech, United States) | FcRn | An engineered FcRn-binding Fc–albumin fusion protein to deplete circulating IgG, including… | https://app.academiclabs.com/search/patents?patent=I2tOFjRPY5wt

- Ascentage Pharma Group (biotech, China) | Macrophage and innate | A broad family of small-molecule epigenetic/immune modulators, including Cpd. | https://app.academiclabs.com/search/patents?patent=rvJmUEXgl6YW

- ImmuNext (biotech, United States) | Macrophage and innate | An anti-VISTA antibody–glucocorticoid ADC platform (including INX/INXSM steroid-linker… | https://app.academiclabs.com/search/patents?patent=in4TLKtOxUlC

- Saga University (academic, Japan) | Macrophage and innate | Elucidation of the pathogenesis of cidp and development of new treatment methods focusing on… | https://app.academiclabs.com/search/projects?project=GhrddIEpkiYs

- The University of Texas Health Science Center at Houston (academic, United States) | Macrophage and innate | Modulation of CSF1R Signaling to Treat Inflammatory Neuropathies. | https://app.academiclabs.com/search/projects?project=G7XEN51QwVtG

- Johannes Gutenberg University Mainz (academic, Germany) | Nerve repair and remyelination | A transdermal aminophylline/theophylline patch for CIDP and other demyelinating neuropathies,… | https://app.academiclabs.com/search/patents?patent=2uR759vHLdwz

- Mayo Foundation for Medical Education and Research (academic, United States) | Nerve repair and remyelination | Short DNA aptamers, including multimeric forms, to stimulate myelin repair/remyelination in… | https://app.academiclabs.com/search/patents?patent=Rt3nImIb51Hi

- Progentos Therapeutics (biotech, United States) | Nerve repair and remyelination | Brain-penetrant PDGFRα-inhibiting small molecules (and potentially antibodies) to promote… | https://app.academiclabs.com/search/patents?patent=wYlRGbyq14lR

- Shenzhen ExoNeuglia Biomedical Technology (biotech, China) | Nerve repair and remyelination | WIN55212-2-enabled production of transplantable oligodendrocyte progenitor cells as a… | https://app.academiclabs.com/search/patents?patent=uy0RYWvYexDa

- The University of Chicago (academic, United Kingdom) | Nerve repair and remyelination | A guanabenz/guanabenz-derivative small-molecule repurposing asset for CIDP and other… | https://app.academiclabs.com/search/patents?patent=X4FJRJ9nGP3j

- MD Healthcare (academic, North Korea) | Other | Extracellular vesicles derived from Sphingomonas bacteria are proposed as a therapeutic… | https://app.academiclabs.com/search/patents?patent=vJOCQKl8GwUW

- MedRegen (biotech, United States) | Other | AMD3100 (plerixafor) plus sub-immunosuppressive tacrolimus is proposed as a… | https://app.academiclabs.com/search/patents?patent=NGEEYrWpkGCy

- The General Hospital Corporation (academic, United States) | Other | A trisulfide-based small-molecule therapeutic approach (GSSSG, pantethine trisulfide, or… | https://app.academiclabs.com/search/patents?patent=pi6MBUHLmZsi

- The University of Hong Kong (academic, Hong Kong) | Other | DDO-7263, a 1,2,4-oxadiazole state-dependent voltage-gated sodium-channel inhibitor with… | https://app.academiclabs.com/search/patents?patent=6N9lEfbNRVKw

- Therabest (biotech, United Kingdom) | Other | An iPSC-derived, mass-expanded NK-cell therapy for potential treatment of CIDP as one of many… | https://app.academiclabs.com/search/patents?patent=2MWq07UnQ176

- Jiangsu Asieris Pharmaceuticals (biotech, China) | T-cell and Treg | A CIDP-relevant disclosed technology is repurposing small-molecule DBH inhibitors,… | https://app.academiclabs.com/search/patents?patent=9R35oHSSyxBI

- Mount Sinai Health System (academic, United States) | T-cell and Treg | A whole-body/high-exposure blue LED phototherapy method (400–490 nm) to activate T cells and… | https://app.academiclabs.com/search/patents?patent=NKnxBU2gF6yO

- EpiVax (biotech, United States) | Tolerance | asset: Tregitopes | IgG-derived Treg epitope peptides proposed as an active component of IVIg, with ex vivo… | https://app.academiclabs.com/organisation/4kUBhOZrWBBd

In vitro or cell data

- Apellis Pharmaceuticals (biotech, United States) | Complement | Small-molecule C3-convertase inhibitors that suppress complement alternative-pathway activity,…

- Alvit LCS Pharma (biotech, Israel) | Cytokine and chemokine | A fixed-dose CBD plus Cordyceps or Reishi combination to suppress pro-inflammatory…

- Catholic University of Louvain (academic, Belgium) | Cytokine and chemokine | Latent-TGFβ1-activating monoclonal antibodies/fragments to suppress pathological immune…

- National Centre for Scientific Research (academic, France) | Cytokine and chemokine | CXCR4-minor-pocket-targeting cyclic isothiourea small molecules that suppress inflammatory…

- Tanabe Pharma Corporation (biotech, Germany) | Cytokine and chemokine | A Tanabe Pharma small-molecule pan-SIK1/2/3 inhibitor series for potential treatment of CIDP…

- Viela Bio (biotech, United States) | Cytokine and chemokine | A CD40L-binding engineered Tn3 protein scaffold as a potential immunomodulatory therapy for…

- Gliknik (biotech, United States) | Fc / FcγR | asset: Stradomers (GL-2045) | Recombinant multimerized IgG1 Fc–IgG2 hinge “stradomer” fusion proteins that polyvalently…

- Draupnir Bio (biotech, Denmark) | FcRn | In CIDP, the relevant disclosed technology is a sortilin-recruiting bifunctional…

- Inhibrx LP (biotech, United States) | FcRn | A multivalent FcRn-blocking VHH biologic, optionally albumin-binding for half-life extension,…

- Coherus BioSciences (biotech, United States) | Macrophage and innate | An anti-ILT4 monoclonal-antibody technology that blocks ILT4-HLA-G/HLA-A immune-inhibitory…

- Consorcio Regenero S.A (biotech, Chile) | Macrophage and innate | A defined extracellular-vesicle preparation from umbilical-cord mesenchymal cells as an…

- Muna Therapeutics (biotech, Denmark) | Macrophage and innate | A small-molecule TREM2 activator/agonist platform to enhance myeloid-cell TREM2-DAP12…

- The Board of Regents of the University of Texas System (academic, United States) | Macrophage and innate | Anti-LILRB3 monoclonal antibodies, particularly LILRB3 agonists, as potential treatments for…

- The Methodist Hospital (academic, United States) | Macrophage and innate | Anti-inflammatory extracellular vesicles derived from expanded regulatory T cells, to suppress…

- Case Western Reserve University (academic, United States) | Nerve repair and remyelination | An anti-Sox6 oligodendrocyte-maturation technology, using nucleic-acid/gene-silencing or…

- Korea Research Institute of Bioscience and Biotechnology (academic, South Korea) | Nerve repair and remyelination | A combined Schwann-cell precursor/Schwann-cell and NK-cell therapy, including directly…

- University of California System (academic, Germany) | Nerve repair and remyelination | Repurposed small-molecule agents, including NK1 inhibitors, H3R antagonists, and CGRP…

- University of Fribourg (academic, Switzerland) | Nerve repair and remyelination | Low-dose theophylline, repurposed as an HDAC1/2 activator, to promote peripheral-nerve…

- Case Western Reserve University (academic, United States) | Other | HDAC3-selective small-molecule inhibitors, including RGFP966, for potential treatment of CIDP…

- Ducentis BioTherapeutics (biotech, United Kingdom) | Other | An engineered high-affinity CD200 receptor agonist fusion protein (mutant CD200–IgG4 Fc) for…

- Eastern Washington University (academic, United States) | Other | An orally administered engineered GABA-producing probiotic, principally modified Lactococcus…

- Gate Bioscience (biotech, United States) | Other | Small-molecule Sec61 protein-translocation inhibitors to reduce secretion of pathogenic…

- Guangzhou Yufan Nantu Biotechnologies (biotech, China) | Other | A Cbl-b-inhibiting heterocyclic small-molecule series for immune modulation and potential…

- Molecure (biotech, Poland) | Other | A portfolio of substituted pyrrolotriazine USP7-inhibitor small molecules for potential…

- Precision Biologics (biotech, United States) | Other | NEO-201 is a glycoepitope-targeting anti-CEACAM5/CEACAM6 antibody proposed for CIDP only under…

- The University of Arizona (academic, United States) | Other | A CIDP-relevant ssDNA aptamer technology designed to bind and neutralize pathogenic…

- The University of Chicago (academic, United States) | Other | Guanabenz, an orally administered small molecule and its derivatives, for CIDP and other…

- Augusta University Research Institute (academic, United States) | T-cell and Treg | A selective small-molecule Akt3 activator platform to enhance FoxP3-positive regulatory T-cell…

- Benethera (Shaoxing) Biotechnology (biotech, China) | T-cell and Treg | The patent discloses O-1602 and novel related small molecules that expand immunoregulatory…

- Dartmouth College (academic, United States) | T-cell and Treg | Metabolically engineered PDK1/PDP1-overexpressing T cells as an adoptive cell-therapy platform…

- Deciduous Therapeutics (biotech, United States) | T-cell and Treg | Novel small-molecule iNKT-cell activators to treat CIDP and other diseases by modulating…

- FibroGenesis (biotech, United States) | T-cell and Treg | An IFNγ-conditioned fibroblast/immune-cell co-culture cell-therapy platform, including…

- Hanyang University (academic, South Korea) | T-cell and Treg | A CTLA4-derived regulatory-T-cell-inducing peptide technology for CIDP, to suppress pathogenic…

- Monash University (academic, Australia) | T-cell and Treg | A CCR6-targeting antibody/antibody-fragment technology to inhibit CCR6–MIP-3α signaling for…

- Odyssey Therapeutics (biotech, United States) | T-cell and Treg | TNFR2-agonist single-domain antibodies and related multivalent fusion proteins designed to…

- The General Hospital Corporation (academic, United States) | T-cell and Treg | An agonistic anti-TNFR2 antibody technology to suppress pathogenic immune activity by…

- University of Glasgow (academic, United Kingdom) | T-cell and Treg | A parasite-derived recombinant TGF-beta mimic protein, TGM, that activates TGF-beta receptors…

- Zealand Pharma a/s (biotech, Denmark) | T-cell and Treg | Engineered PaT1-derived peptide potassium-channel blockers, described as Kv1.3 in the…

- Zelarion Malta (biotech, Malta) | T-cell and Treg | A CIDP-relevant combination immunotherapy of anti-CD2 T-cell targeting (notably siplizumab)…

Concept or no data disclosed

- AB Biosciences (biotech, United States) | B-cell and plasma-cell | A sequence-defined multimeric IgM bispecific anti-CD38/anti-CD3…

- Nurix Therapeutics (biotech, United States) | B-cell and plasma-cell | BTK-targeting bifunctional small-molecule degraders (BTK PROTAC-like…

- The Francis Crick Institute (academic, United Kingdom) | B-cell and plasma-cell | Neuritin-based protein, gene-delivery, or neuritin-expressing cell…

- Artiva Biotherapeutics (biotech, United States) | CAR-T | A BCMA-targeted, IL-15-enabled CAR-NK cell/antibody platform for…

- Lyell Immunopharma (biotech, United States) | CAR-T | CD19/CD20-directed bispecific CAR immune-cell therapy, primarily…

- Shanghai Nuogang Exhibition (biotech, China) | CAR-T | A CD19/BCMA dual-target CAR-T-cell technology to deplete autoreactive…

- Bastion Therapeutics (biotech, United Kingdom) | Complement | An inducible, tissue-targeted engineered cell therapy—preferably a…

- Leal Therapeutics (biotech, United States) | Complement | C3-targeting oligonucleotides that modulate C3 mRNA for potential…

- Montis Biosciences (biotech, Belgium) | Complement | asset: MB0109 (MB01) | Anti-C1q antibody that blocks C1q-driven macrophage activation and…

- MorphoSys (biotech, Germany) | Complement | A sequence-defined anti-C5aR monoclonal antibody technology for…

- AlonBio (biotech, Israel) | Cytokine and chemokine | A chemically defined small-molecule series that modulates chemokine…

- Crescendo Biologics (biotech, United Kingdom) | Cytokine and chemokine | An IL-17A-neutralizing antibody-fragment technology for treating CIDP…

- Earendil Labs (biotech, United States) | Cytokine and chemokine | A sequence-defined TL1A × IL-23p19 bispecific antibody asset for…

- Exocure Sweden (biotech, Sweden) | Cytokine and chemokine | Engineered extracellular vesicles from cells overexpressing selected…

- National Center of Neurology and Psychiatry (academic, Japan) | Cytokine and chemokine | An orally administered glycolipid small-molecule immunomodulator that…

- Regrow Biosciences Private (biotech, India) | Cytokine and chemokine | An MSC cell-therapy composition enriched/characterized by VEGF and…

- Remepy Health (biotech, Israel) | Cytokine and chemokine | An adaptive sensory-based digital therapeutic, optionally combined…

- Sudo Biosciences (biotech, United Kingdom) | Cytokine and chemokine | A portfolio of novel small-molecule TYK2 inhibitors to suppress…

- The Board of Regents of the University of Texas System (academic, United States) | Cytokine and chemokine | sIL7R-selective neutralizing antibodies for potential treatment of…

- The General Hospital Corporation (academic, United States) | Cytokine and chemokine | An agonistic anti-TNFR2 antibody technology, exemplified by 8ED1, is…

- Valorisation-Recherche Partnership (biotech, Canada) | Cytokine and chemokine | A peptide-like IL-1 receptor inhibitor/modulator for treating CIDP as…

- Zhejiang Wenda Pharmaceutical Technology (biotech, United Kingdom) | Cytokine and chemokine | A novel heterocyclic TYK2-inhibitor small-molecule series, including…

- Seismic Therapeutic (biotech, United States) | Fc / FcγR | Engineered FcγRIIb-selective IgG Fc variants and Fc-fusion molecules…

- Dartmouth College (academic, United States) | Macrophage and innate | A BRI3-silencing gene/RNA therapeutic concept to suppress…

- Electra Therapeutics (biotech, United States) | Macrophage and innate | Human monoclonal anti-SIRPγ/anti-SIRPα and/or SIRPβ1 antibodies for…

- Inotrem (biotech, France) | Macrophage and innate | Sequence-defined anti-TREM-1 monoclonal antibodies/fragments to…

- Kaigene (biotech, United States) | Macrophage and innate | A humanized anti-CD11b (ITGAM) antibody therapeutic for treating CIDP…

- Physis International (biotech, United States) | Macrophage and innate | Fluorinated, optionally metal/anion-chelated tilmanocept constructs…

- Temper Bio (biotech, France) | Macrophage and innate | asset: TAFA4-based biologic | First-in-class TAFA4 neurokine platform for neuroinflammation with…

- University of Florida Research Foundation (academic, United States) | Macrophage and innate | SR1903, a polypharmacologic small molecule that inhibits TREM-1 while…

- Autobahn Therapeutics (biotech, United States) | Nerve repair and remyelination | FAAH-cleavable thyromimetic small-molecule prodrugs combined with a…

- Brittney A. Beyer (The Scripps Research Institute) (academic, United States) | Nerve repair and remyelination | A small-molecule remyelination combination using an RXRγ agonist plus…

- Cysay (biotech, Japan) | Nerve repair and remyelination | An acellular secretome/culture-supernatant product from engineered…

- Johannes Gutenberg-Universität Mainz (academic, Germany) | Nerve repair and remyelination | A transdermal aminophylline/theophylline patch designed to promote…

- Larimar Therapeutics (biotech, United States) | Nerve repair and remyelination | A frataxin replacement fusion-protein technology for treating CIDP as…

- Medical University of Vienna (academic, Austria) | Nerve repair and remyelination | A cyclotide–KOR ligand combination, including T20K and related…

- Teejin Pharma (biotech, Japan) | Nerve repair and remyelination | In CIDP, the patent discloses vitamin D derivative candidates…

- Vanderbilt University (academic, United States) | Nerve repair and remyelination | Anacardic acid is a small-molecule neural-repair therapy proposed to…

- Wisconsin Alumni Research Foundation (academic, United States) | Nerve repair and remyelination | A Schwann-cell-targeted gene-expression platform using regulatory DNA…

- Ageronix (biotech, Switzerland) | Other | AAT-based ADAM17-inhibitory therapy, including use with IVIG/IgG, for…

- Alphabet (biotech, United States) | Other | Small-molecule integrated stress response modulators, likely acting…

- Augustine Therapeutics (biotech, Belgium) | Other | A series of small-molecule HDAC6 inhibitors for treatment of CIDP as…

- Coave Therapeutics (biotech, France) | Other | A surface-saccharide-modified AAV viral-vector gene-delivery platform…

- Denali Therapeutics (biotech, United States) | Other | A Denali small-molecule receptor-interacting protein kinase 1 (RIPK1)…

- Health Research (biotech, United States) | Other | Anti-survivin therapeutic antibodies, including defined…

- InSilico Medicine (biotech, United States) | Other | A QPCTL-targeting beta-lactam small-molecule inhibitor platform for…

- James Cook University (academic, United Kingdom) | Other | Modified Ac-TMP-2 is an engineered anti-inflammatory protein…

- Keros Therapeutics (biotech, United States) | Other | An engineered ActRII ligand-trap fusion protein platform from Keros…

- Konkuk University Industry Cooperation Foundation (academic, South Korea) | Other | A recombinant AAT–immunoglobulin Fc fusion protein as an…

- LDC Beteiligungen UG (Lead Discovery Center) (academic, Germany) | Other | A novel macrocyclic small-molecule proteasome/immunoproteasome beta-5…

- Leiden University (academic, Netherlands) | Other | GBA2-cleavable glycosylated anti-inflammatory, particularly…

- Lirum Therapeutics (biotech, United States) | Other | An IGF1R ligand–disease-modifying agent conjugate, including…

- Mass General Brigham (academic, United States) | Other | EphB3-targeting small-molecule kinase inhibitors for treatment of…

- Mordechai Chevion (Hebrew University of Jerusalem) (academic) | Other | A non-iron metal-desferrioxamine B complex, particularly ZnDFO and/or…

- Nalu Bio (biotech, (Country unavailable)) | Other | A novel aryl-substituted N-alkyl indole small-molecule series is…

- Nationwide Children's Hospital (academic, United States) | Other | An intramuscular rAAV-mediated NT-3 gene therapy to provide sustained…

- Neuropore Therapies (biotech, United States) | Other | Novel small-molecule TLR2/TRL9 signaling modulators for potential…

- OSE Immunotherapeutics (biotech, France) | Other | An FcRn–beta2-microglobulin–antigen fusion/protein platform to…

- RSCI Royal College of Surgeons in Ireland (academic, Ireland) | Other | An endothelial-targeted PfEMP1 CIDRα4 fusion-protein platform,…

- Rapport Therapeutics (biotech, United States) | Other | A CIDP-relevant asset is a series of azabenzimidazole small-molecule…

- Remepy Health (biotech, Israel) | Other | An adaptive sensory-based digital therapeutic, used with nondigital…

- Royston A. Gray (Jazz Pharmaceuticals) (biotech, United Kingdom) | Other | Synthetic mesembrine-alkaloid-related small molecules as potential…

- Senseion Therapeutics (biotech, United States) | Other | Small-molecule inflammasome-suppressing compounds for treatment of…

- Sitryx Therapeutics (biotech, United Kingdom) | Other | A Sitryx small-molecule series of 2-methylene-4-oxo-butanoic acid…

- St Phi Therapeutics (biotech, China) | Other | An ERAD-based targeted-protein-degradation fusion-protein platform,…

- Suntec Medical (biotech, United States) | Other | A PEG–EGCG/polymer-flavonoid conjugate, flavonoid oligomer, and…

- Synlogic Operating Company (biotech, United States) | Other | An engineered live bacterium, potentially E.

- Toray Industries (biotech, Japan) | Other | A specified cyclic-amine small-molecule series for treating…

- Verge Analytics (biotech, United States) | Other | A PIKfyve-inhibiting pyrazolo-pyrimidine small-molecule prodrug…

- Vivoryon Therapeutics (biotech, Germany) | Other | Small-molecule glutaminyl cyclase (QC) inhibitors for potential…

- Wageningen University & Research (academic, Netherlands) | Other | Desulfovibrio-based live biotherapeutic microbiome therapy,…

- Wobble Genomics (biotech, United Kingdom) | Other | A blood-RNA sequencing and biomarker platform, including personalized…

- Yale University (academic, United States) | Other | A broad antibody–cellular-receptor molecular-degrader platform for…

- iCell Gene Therapeutics (biotech, United States) | Other | An ex vivo engineered CAR-T or CAR-NK platform, particularly…

- Alpine Immune Sciences (biotech, United States) | T-cell and Treg | A recombinant CTLA-4–Fc–PD-L1 IgV immunomodulatory fusion protein for…

- Consorcio Regenero S.A (biotech, Chile) | T-cell and Treg | A defined umbilical-cord mesenchymal-cell extracellular-vesicle…

- Monte Rosa Therapeutics (biotech, United States) | T-cell and Treg | A small-molecule VAV1 degrader for immune-mediated diseases including…

- Nimbus Clotho (biotech, United States) | T-cell and Treg | Small-molecule CTPS1 inhibitors to suppress pathogenic lymphocyte…

- Nutcracker Therapeutics (biotech, United States) | T-cell and Treg | An ex vivo mRNA-nanoparticle antigen-presentation platform for…

- University of Pennsylvania (academic, United States) | T-cell and Treg | CIDP is included as a named autoimmune neuropathy within a proposed…

- Yale University (academic, United States) | T-cell and Treg | A TCR Vβ-targeted antibody/CAR-T platform for selective depletion or…

- Baylor Research Institute (academic, United States) | Tolerance | An ASGPR-targeted dendritic-cell antibody fusion/conjugate carrying…

- Integrated Nanotherapeutics (biotech, Canada) | Tolerance | An antigen-specific tolerogenic lipid-nanoparticle/liposome…

- Lapix Therapeutics (biotech, United States) | Tolerance | Amino-acid immunotolerizing compositions to induce…

- Nykode (biotech, Norway) | Tolerance | A non-viral or viral vector-based antigen-specific immune-tolerance…

- Orchard Therapeutics (Europe) (biotech, United Kingdom) | Tolerance | Genetically engineered hematopoietic stem/progenitor cells programmed…

- Regents of the University of Michigan (academic, United States) | Tolerance | Antigen-coupled tolerizing immune modified particles (TIMPs) as an…

- Topas Therapeutics (biotech, Germany) | Tolerance | An antigen-specific tolerogenic nanoparticle platform carrying…

- Zag Bio (biotech, United States) | Tolerance | An antigen-specific immune-tolerance biologic that targets thymic or…

PARTNERING: TOP PARTNERABLE ORGANISATIONS (outside the established CIDP companies)

- Dianthus Therapeutics Opco, Inc. (Biotech / SME, United States) · CIDP stage: Phase 3 · sources: patents, company, studies · Phase 3, active study, latest 2025, 3 sources · Claseprubart

- Immunovant (Biotech / SME, United States) · CIDP stage: Phase 2 · sources: patents, company, studies · Phase 2, active study, CIDP-primary patent, latest 2025, 3 sources · Batoclimab, Imeroprubart

- Kine Sciences (Biotech / SME, South Korea) · CIDP stage: Phase 1 · sources: patents, company, studies, news · Phase 1, CIDP-primary patent, latest 2025, 4 sources · KINE-101

- Hanall Biopharma Co Ltd (Biotech / SME, South Korea) · CIDP stage: Phase 3 · sources: patents, company, news · Phase 3, latest 2023, 3 sources · Batoclimab

- Stichting Amsterdam UMC (Academic / hospital) · CIDP stage: Phase 3 · sources: patents, studies · Phase 3, active study, latest 2024 · Rituximab

- The University of Kansas (Academic / hospital, United States) · CIDP stage: Phase 2 · sources: patents, studies, researchers · Phase 2, latest 2025, 3 sources · Rituximab

- Johns Hopkins University (Academic / hospital, United States) · CIDP stage: Phase 3 · sources: patents, studies · Phase 3, latest 2026 · Alemtuzumab

- Nagoya University (Academic / hospital, Japan) · CIDP stage: Phase 2 · sources: studies, projects, researchers · Phase 2, open mechanism, latest 2025, 3 sources · Rituximab

- Zhongming Qiu (Investigator / other) · CIDP stage: Phase 3 · sources: studies · Phase 3, active study, latest 2026 · Obinutuzumab, Ripertamab

- Alpine Immune Sciences, Inc. (Biotech / SME) · CIDP stage: Preclinical · sources: patents · Preclinical, clinical in another indication, latest 2025 · B cells

- Gliknik (Biotech / SME, United States) · CIDP stage: Preclinical · sources: patents, company · Preclinical, latest 2024 · Stradomers (GL-2045)

- Nuvig Therapeutics (Biotech / SME, United States) · CIDP stage: Phase 2 · sources: company, studies · Phase 2, active study, latest 2025 · NVG-2089

- TG Therapeutics Inc (Biotech / SME, United States) · CIDP stage: Phase 2 · sources: company, studies · Phase 2, active study, latest 2025 · Azer-cel

- Apellis Pharmaceuticals Inc (Biotech / SME, United States) · CIDP stage: Preclinical · sources: patents, company, news · Preclinical, latest 2024, 3 sources · Complement pathway

- St Vincent's Hospital Sydney (Academic / hospital, Australia) · CIDP stage: Phase 2 · sources: studies · Phase 2, active study, latest 2024 · aHSCT

- Viela Bio (Biotech / SME) · CIDP stage: Preclinical · sources: patents · Preclinical, clinical in another indication, latest 2025 · B cells

- Western Sydney Local Health District (Academic / hospital) · CIDP stage: Phase 2 · sources: studies · Phase 2, active study, latest 2024 · Rituximab

- Yale University (Academic / hospital, United States) · CIDP stage: Discovery / IP · sources: patents, projects · Discovery / IP, open mechanism, latest 2026 · Efgartigimod, Rozanolixizumab

- Muna Therapeutics (Biotech / SME, Denmark) · CIDP stage: Preclinical · sources: patents, company · Preclinical, latest 2025 · Macrophages/monocytes

- The General Hospital Corporation (Academic / hospital) · CIDP stage: Preclinical · sources: patents · Preclinical, latest 2025 · Unspecified / multifactorial

- University of Florida Research Foundation, Incorporated (Academic / hospital) · CIDP stage: Preclinical · sources: patents, researchers · Preclinical, latest 2025 · Macrophages/monocytes

- Alvit LCS Pharma (Biotech / SME, Israel) · CIDP stage: Preclinical · sources: patents, company · Preclinical, latest 2025 · Cytokine signaling

- Ascentage Pharma Group Corp Limited (Biotech / SME, China) · CIDP stage: Preclinical · sources: patents, company · Preclinical, latest 2023 · Macrophages/monocytes

- Autobahn Therapeutics (Biotech / SME, United States) · CIDP stage: Preclinical · sources: patents, company · Preclinical · Myelin repair/regeneration

- Juventas Cell Therapy Ltd (Biotech / SME, China) · CIDP stage: Phase 1 · sources: company, studies · Phase 1, active study, latest 2025 · CNCT19, HY001N

- Regrow Biosciences Private Limited (Biotech / SME) · CIDP stage: Preclinical · sources: patents · Preclinical, latest 2025 · Cytokine signaling

- Sitryx Therapeutics (Biotech / SME) · CIDP stage: Preclinical · sources: patents · Preclinical, latest 2023 · Other

- Tongji Hospital (Academic / hospital, China) · CIDP stage: Phase 1 · sources: studies, researchers · Phase 1, active study, latest 2026 · BCMA CAR-T (other), JY231, QH103, RD06-05, Universal CD19/BCMA CAR-T

- Augustine Therapeutics (Biotech / SME) · CIDP stage: Preclinical · sources: patents · Preclinical, latest 2025 · Other

- Draupnir Bio (Biotech / SME, Denmark) · CIDP stage: Preclinical · sources: patents, company · Preclinical, latest 2023 · Immunoglobulin G depletion

EXPERTS: TOP 40 CIDP RESEARCHERS (name · affiliation · country · role · drugs named · industry ties · AcademicLabs profile)

- Filip Eftimov · Amsterdam University Medical Centres · Netherlands · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab, Rozanolixizumab · ties: UCB, argenx

- Luís Querol · Hospital de la Santa Creu i Sant Pau · Spain · Novel-therapy clinical development · drugs: Efgartigimod, Empasiprubart, Riliprubart, Rituximab · ties: Sanofi, UCB, argenx

- Masahiro Iijima · Nagoya University · Japan · Novel-therapy clinical development · drugs: Rituximab · ties: none recorded

- Dai-Shi Tian · Tongji Hospital · China · Novel-therapy clinical development · drugs: Universal CD19/BCMA CAR-T, JY231, QH103, RD06-05 · ties: none recorded

- Eduardo Nobile-Orazio · Humanitas Research Hospital · Italy · Novel-therapy clinical development · drugs: Efgartigimod, Nipocalimab, Rituximab, LFB Ig (I10E / Iqymune) · ties: Johnson & Johnson, LFB, argenx

- Jeffrey A. Allen · University of Minnesota Twin Cities · United States · Novel-therapy clinical development · drugs: Efgartigimod, Empasiprubart, Riliprubart · ties: CSL, Sanofi, argenx

- Jeffrey T. Guptill · Duke University School of Medicine · United States · Novel-therapy clinical development · drugs: Efgartigimod, Riliprubart · ties: Sanofi, argenx

- Satoshi Kuwabara · Chiba University · Japan · Novel-therapy clinical development · drugs: Efgartigimod, Nipocalimab, Rituximab, HyQvia (TAK-771) · ties: Takeda, argenx

- Chuan Qin · Tongji Hospital · China · Novel-therapy clinical development · drugs: Universal CD19/BCMA CAR-T, JY231, QH103, RD06-05 · ties: none recorded

- Pieter A. van Doorn · Erasmus University Rotterdam · Netherlands · Novel-therapy clinical development · drugs: Efgartigimod, Riliprubart · ties: Sanofi, argenx

- Simon Rinaldi · University of Oxford · United Kingdom · Novel-therapy clinical development · drugs: Efgartigimod, Empasiprubart, Rituximab · ties: argenx

- Pietro Emiliano Doneddu · Humanitas Research Hospital · Italy · Novel-therapy clinical development · drugs: Empasiprubart, Rituximab · ties: argenx

- Johannes Jakobsen · Rigshospitalet · Denmark · Treatment evidence & optimisation · drugs: Hizentra (IgPro20), Privigen (IgPro10), HyQvia (TAK-771), Gammagard / Kiovig · ties: none recorded

- Benjamin Van Hoorick · argenx BV · United States · Novel-therapy clinical development · drugs: Efgartigimod · ties: argenx

- Thomas Skripuletz · Hannover Medical School · Germany · Novel-therapy clinical development · drugs: Efgartigimod, Hizentra (IgPro20) · ties: argenx

- Vera Bril · University of Toronto · Canada · Novel-therapy clinical development · drugs: Efgartigimod, Nipocalimab, Rozanolixizumab, Batoclimab · ties: Takeda

- Chafic Karam · University of Pennsylvania · United States · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab · ties: argenx

- Mamatha Pasnoor · The University of Kansas · United States · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab, Acthar gel, HyQvia (TAK-771) · ties: Takeda, argenx

- Masahisa Katsuno · Nagoya University · Japan · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab · ties: argenx

- Inge Van de Walle · argenx BV · United States · Novel-therapy clinical development · drugs: Empasiprubart · ties: argenx

- Geoffrey Istas · argenx BV · United States · Novel-therapy clinical development · drugs: Efgartigimod · ties: argenx

- Erik Hofman · argenx BV · United States · Novel-therapy clinical development · drugs: Efgartigimod · ties: argenx

- Richard A. Lewis · Cedars-Sinai Health System · United States · Novel-therapy clinical development · drugs: Efgartigimod, Riliprubart · ties: Sanofi, argenx

- Roger Collet-Vidiella · Hospital de la Santa Creu i Sant Pau · Spain · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab · ties: argenx

- Mazen Dimachkie M.D. · The University of Kansas · United States · Novel-therapy clinical development · drugs: Efgartigimod, Riliprubart, Rituximab, Hizentra (IgPro20) · ties: none recorded

- Ingemar S. J. Merkies · University of Curacao Dr Moises da Costa Gomez · Curaçao · Novel-therapy clinical development · drugs: Efgartigimod, Riliprubart, Nipocalimab, Hizentra (IgPro20) · ties: CSL, Johnson & Johnson, Octapharma

- Motoi Kuwahara · Kindai University · Japan · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab · ties: CSL, argenx

- Yusuf A. Rajabally · NIHR Surgical Reconstruction Microbiology Research Centre · United Kingdom · Novel-therapy clinical development · drugs: Efgartigimod, Riliprubart, Nipocalimab, Batoclimab · ties: Dianthus Therapeutics, Johnson & Johnson, LFB

- Kalliopi Pitarokoili · St. Josef-Hospital · Germany · Novel-therapy clinical development · drugs: Efgartigimod · ties: argenx

- Karissa Gable · Duke University Medical Center · United States · Novel-therapy clinical development · drugs: Efgartigimod, Empasiprubart, Riliprubart · ties: Sanofi, argenx

- Miguel Alonso-Alonso · Sanofi · France · Novel-therapy clinical development · drugs: Riliprubart · ties: Sanofi

- Shahar Shelly · Rambam Health Care Campus · Israel · Diagnosis & biomarkers · drugs: Rituximab · ties: none recorded

- Ivana Basta · University of Belgrade · Serbia · Novel-therapy clinical development · drugs: Efgartigimod, HyQvia (TAK-771) · ties: Takeda, argenx

- Elba Pascual-Goñi · Network of Biomedical Research Centers · Spain · Novel-therapy clinical development · drugs: Efgartigimod, Rituximab · ties: argenx

- Krista Kuitwaard · Erasmus University Rotterdam · Netherlands · Treatment evidence & optimisation · drugs: Gammagard / Kiovig · ties: none recorded

- Dario Cocito · University of Turin · Italy · Novel-therapy clinical development · drugs: Rituximab, HyQvia (TAK-771), Gammagard / Kiovig · ties: Takeda

- Aisling Carr · University College London · United Kingdom · Novel-therapy clinical development · drugs: Efgartigimod · ties: argenx

- Todd Levine · HonorHealth · United States · Novel-therapy clinical development · drugs: Efgartigimod, Rozanolixizumab, HyQvia (TAK-771), Gammagard / Kiovig · ties: Takeda, UCB

- Yuki Fukami · Nagoya University · Japan · Novel-therapy clinical development · drugs: Rituximab · ties: none recorded

- Johannes Dorst · Ulm University · Germany · Treatment evidence & optimisation · drugs: - · ties: none recorded

WHITESPACE: EVIDENCE BY BIOLOGY AXIS (publications · patent families · clinical studies)

- FcRn / Fc receptor: 96 publications (68% human) · 22 patent families (5 CIDP-primary) · 14 studies (6 active) · 4 funded projects · patent holders: argenx BV, Gliknik, Hanall Biopharma Co Ltd, Seismic Therapeutic Inc, Immunovant Sciences GmbH

- Complement: 15 publications (80% human) · 28 patent families (4 CIDP-primary) · 8 studies (6 active) · 4 funded projects · patent holders: Dianthus Therapeutics Opco, Inc., Bioverativ USA Inc., argenx BV, MorphoSys AG, AstraZeneca

- B cells / plasma cells: 38 publications (74% human) · 20 patent families (0 CIDP-primary) · 21 studies (14 active) · 4 funded projects · patent holders: The Francis Crick Institute, Nurix Therapeutics Inc, Biogen, IGM Biosciences Inc, Amgen

- T cells / Treg: 19 publications (79% human) · 45 patent families (0 CIDP-primary) · 0 studies (0 active) · 0 funded projects · patent holders: Augusta University Research Institute,, Alpine Immune Sciences, Inc., Monte Rosa Therapeutics Inc, Coya Therapeutics, Adimab LLC

- Nodal/paranodal autoantibodies: 48 publications (83% human) · 5 patent families (0 CIDP-primary) · 0 studies (0 active) · 11 funded projects · patent holders: The University of Arizona, Arizona Board of Regents, OSE Immunotherapeutics, Novartis, Yale University

- Cytokine / chemokine: 18 publications (61% human) · 28 patent families (0 CIDP-primary) · 0 studies (0 active) · 0 funded projects · patent holders: National Centre for Scientific Researc, The University of Texas System, Alvit LCS Pharma, AlonBio Ltd., Earendil Labs

- Macrophage / innate: 6 publications (33% human) · 22 patent families (0 CIDP-primary) · 0 studies (0 active) · 1 funded projects · patent holders: Bristol-Myers Squibb, University of Florida Research Foundat, Muna Therapeutics, Novartis, Electra Therapeutics

- Schwann cell / remyelination: 6 publications (67% human) · 30 patent families (1 CIDP-primary) · 1 studies (0 active) · 4 funded projects · patent holders: Autobahn Therapeutics, Cysay Inc., Teijin Ltd, Kine Sciences, Vanderbilt University

- Axonal protection: 55 publications (53% human) · 2 patent families (1 CIDP-primary) · 0 studies (0 active) · 0 funded projects · patent holders: Vanda Pharmaceuticals Inc

- Antigen-specific tolerance: 0 publications (0% human) · 12 patent families (0 CIDP-primary) · 0 studies (0 active) · 0 funded projects · patent holders: Nykode, Topas Therapeutics, Baylor Research Institute, Regents of the University of Michigan, Integrated Nanotherapeutics

- Genetic susceptibility: 25 publications (60% human) · 0 patent families (0 CIDP-primary) · 0 studies (0 active) · 0 funded projects · patent holders: -

- Blood-nerve barrier: 2 publications (0% human) · 0 patent families (0 CIDP-primary) · 0 studies (0 active) · 0 funded projects · patent holders: -

DEVELOPERS: EVIDENCE LADDER

- argenx: Marketed in CIDP — Efgartigimod approved; empasiprubart (anti-C2) in two Phase 3 trials · 9 studies (6 active) · 10 patent families · 51 publications

- CSL: Marketed in CIDP — Active or planned: Hizentra (IgPro20), Privigen (IgPro10) (2 studies) · 12 studies (4 active) · 4 patent families · 10 publications

- Takeda: Marketed in CIDP — HyQvia approved for CIDP maintenance (FDA and EU, January 2024) · 9 studies (4 active) · 2 patent families · 10 publications

- Octapharma: Marketed in CIDP — Active or planned: Octapharma Ig (Panzyga / NewGam / Octagam) (2 studies) · 7 studies (3 active) · 0 patent families · 1 publications

- Grifols: Marketed in CIDP — Active or planned: Grifols Ig (Gamunex / Xembify), Hizentra (IgPro20) (2 studies) · 5 studies (2 active) · 0 patent families · 0 publications

- Sanofi: Active clinical — Phase 3 MOBILIZE (riliprubart) discontinued for futility, June 2026 · 6 studies (3 active) · 8 patent families · 17 publications

- Immunovant: Active clinical — Batoclimab Phase 2b; imeroprubart Phase 2 active · 3 studies (2 active) · 4 patent families · 1 publications

- Juventas Cell Therapy: Active clinical — Active or planned: CNCT19, HY001N (2 studies) · 2 studies (2 active) · 0 patent families · 0 publications

- Kedrion: Active clinical — Active or planned: immunoglobulin (1 study) · 4 studies (2 active) · 0 patent families · 0 publications

- Dianthus Therapeutics: Active clinical — Early GO in Phase 3 CAPTIVATE (claseprubart), March 2026 · 1 studies (1 active) · 4 patent families · 0 publications

- Johnson & Johnson: Active clinical — Nipocalimab Phase 2/3 (ARISE) · 1 studies (1 active) · 4 patent families · 5 publications

- Nuvig Therapeutics: Active clinical — Active or planned: NVG-2089 (1 study) · 1 studies (1 active) · 0 patent families · 2 publications

- Kite (Gilead): Active clinical — Active or planned: KITE-363 (1 study) · 1 studies (1 active) · 0 patent families · 0 publications

- TG Therapeutics: Active clinical — Active or planned: Azer-cel (1 study) · 1 studies (1 active) · 0 patent families · 0 publications

- Halozyme: Technology partner — Subcutaneous delivery technology (ENHANZE) in the efgartigimod SC approvals · 0 studies (0 active) · 0 patent families · 1 publications

- LFB: Clinical, none active — Completed or stopped: LFB Ig (I10E / Iqymune) · 4 studies (0 active) · 0 patent families · 0 publications

- UCB: Clinical, none active — Completed or stopped: Rozanolixizumab · 3 studies (0 active) · 0 patent families · 1 publications

- Pfizer: Clinical, none active — Completed or stopped: PF-06755347 · 1 studies (0 active) · 2 patent families · 0 publications

- Kine Sciences: Clinical, none active — KINE-101 Phase 1b/2a, first patient dosed September 2024 · 1 studies (0 active) · 2 patent families · 0 publications

- Biogen: Clinical, none active — Completed or stopped: Interferon beta-1a · 2 studies (1 active) · 1 patent families · 0 publications

- MedDay Pharmaceuticals: Clinical, none active — Completed or stopped: MD1003 (biotin) · 1 studies (0 active) · 0 patent families · 0 publications

- Nihon Pharmaceutical: Clinical, none active — Completed or stopped: NPB-01 · 1 studies (0 active) · 0 patent families · 0 publications

- Novartis: Collaborator / non-drug study — Named as collaborator, not sponsor, on CIDP studies · 2 studies (0 active) · 5 patent families · 0 publications

- AstraZeneca / Alexion: Collaborator / non-drug study — Named as collaborator, not sponsor, on CIDP studies · 2 studies (1 active) · 2 patent families · 0 publications

- Teijin: Collaborator / non-drug study — Named as collaborator, not sponsor, on CIDP studies · 1 studies (0 active) · 2 patent families · 0 publications

KEY QUESTIONS

What is CIDP, and how is it treated in 2026?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease in which the immune system damages myelin, the insulation around the peripheral nerves, causing weakness and loss of sensation. First treatment is immunoglobulin (IVIg, or subcutaneous immunoglobulin at home), corticosteroids or plasma exchange. The FcRn blocker efgartigimod (Vyvgart Hytrulo) became the first approved non-immunoglobulin option in June 2024 in the US and June 2025 in the EU; HyQvia was approved for maintenance in January 2024. Standard of care →

Which drugs are in clinical development for CIDP?

As of September 2026 the registries hold 216 CIDP-relevant clinical studies, 70 active and 23 planned. The late-stage novel drugs are FcRn blockers (efgartigimod, approved; nipocalimab, M281, in Phase 2/3; imeroprubart, IMVT-1402, in Phase 2), complement inhibitors (riliprubart, SAR445088; empasiprubart, ARGX-117; claseprubart, DNTH103; all in Phase 3) and B-cell depletion (rituximab and ripertamab in Phase 3). 11 CAR-T studies list CIDP, all Phase 1 or 1/2. Immunoglobulin is still the largest class, with 76 studies. Pipeline →

Which CIDP trials read out in 2027?

17 of the 39 registered primary completions between 2026 and 2030 fall in 2027, 10 of them Phase 2/3 or later. The key ones are nipocalimab's ARISE study ( NCT05327114 , May), riliprubart's VITALIZE ( NCT06290141 , July, against IVIg), empasiprubart's EMVIGORATE ( NCT06920004 , September, against IVIg) and EMNERGIZE ( NCT07091630 , October, against placebo), and an academic Phase 3 of rituximab at Amsterdam UMC ( NCT06714838 , October). Registry dates are sponsor estimates and often move. Readout calendar →

Which new CIDP drugs are compared head-to-head with IVIg?

Only 2 of the 32 active or planned studies of novel agents compare directly with IVIg: Sanofi's VITALIZE (riliprubart) and argenx's EMVIGORATE (empasiprubart), both with primary completion registered for 2027. The others compare with placebo, run as single-arm studies or use other designs, so there will be little direct evidence against today's standard of care. Readout calendar →

What have published trials shown for new CIDP drugs?

Of the 180 CIDP treatment publications from 2024 to 2026 read for this report, only one new mechanism has a positive randomised result: efgartigimod in ADHERE, where 27.9% of responders relapsed on the drug against 53.6% on placebo (hazard ratio 0.39). Rituximab as a way off IVIg, steroid pulses added to IVIg and rozanolixizumab in a Phase 2a did not beat their controls. IVIg itself more than doubles the chance of meaningful improvement over placebo (risk ratio 2.40). Trial results →

Why was Sanofi's MOBILIZE trial of riliprubart stopped?

Sanofi stopped the Phase 3 MOBILIZE study of riliprubart (anti-C1s) in refractory CIDP for futility on 10 June 2026, after an interim review. Its second Phase 3, VITALIZE, which compares riliprubart with IVIg, continues. The other two late-stage complement antibodies, claseprubart (Dianthus Therapeutics) and empasiprubart (argenx), remain in Phase 3. Ten findings →

Which companies are developing CIDP treatments?

19 company records show a corroborated active CIDP clinical programme (several belong to the same group). Marketed in CIDP: argenx, Takeda, CSL, Octapharma and Grifols (efgartigimod, HyQvia and immunoglobulin products). Active clinical programmes: Sanofi, Johnson & Johnson, Immunovant, Dianthus Therapeutics, Kedrion, Nuvig Therapeutics, Juventas Cell Therapy, Kite (Gilead) and TG Therapeutics. Developers →

Who are the leading CIDP experts working with?

Of 1,115 researchers with a substantiated CIDP record, 204 have a documented industry tie, and 106 of them are tied to argenx, more than to CSL, Sanofi and Takeda combined (89). 41 of the 50 most-connected researchers have at least one tie. India, South Korea, Poland, Greece, Turkey, Canada and Brazil hold 189 CIDP researchers but only 8 CIDP studies between them. Experts →

Who are the most active CIDP researchers?

Ranked by the report's transparent score (role, linked publications, studies, patents and projects, drugs named, evidence and recency), the most connected academic CIDP researchers in the records are Filip Eftimov, Luís Querol, Masahiro Iijima, Dai-Shi Tian, Eduardo Nobile-Orazio, Jeffrey A. Allen, Jeffrey T. Guptill, Satoshi Kuwabara, Chuan Qin and Pieter A. van Doorn. 41 of the 50 highest-ranked researchers have at least one industry tie. The Experts section lists the top 100 of the 1,115 researchers with a substantiated CIDP record, with their country, role, drugs named and industry ties. Experts →

Which preclinical CIDP programmes are there, and how well validated are they?

Beyond the clinic, the report lists 157 preclinical programmes from 146 developers that have no CIDP clinical study, from CIDP patent families, funded projects and company records. 8 use a drug already clinical in another disease (Alpine Immune Sciences, Viela Bio, Kyverna Therapeutics, EpicentRx, Biocodex (Etifoxine)), 21 have in vivo or patient-sample data, 39 in vitro or cell data, and 89 disclose no data yet. 87 of them work on biology with no active CIDP study: T cells and Treg, tolerance, cytokines, macrophages and nerve repair. The outer ring of the pipeline bullseye and the table under it list every programme. Pipeline →

What is the nodal (paranodal) antibody subgroup of CIDP, and is anyone targeting it?

Antibodies against proteins of the node of Ranvier (neurofascin-155, contactin-1, Caspr1, neurofascin-140/186) define the one CIDP subgroup with a known antigen. It is the most human-grounded topic in the literature (48 publications, 83% with patient data) and the largest theme in public funding (11 of 30 projects), yet no clinical study targets these antibodies. Of 178 researchers working on them, 12% have an industry tie. These patients respond poorly to IVIg and well to rituximab (6 of 8, retrospective). Biology →

Where are the partnering opportunities in CIDP?

332 organisations own or run something partnerable in CIDP: 250 biotechs and SMEs, 78 universities and hospitals and 4 individual investigators. 172 of them hold no CIDP patent family, and 18 academic or investigator sponsors already test new drugs without a big company. Patents also run ahead of evidence: T-cell approaches account for 45 patent families that name CIDP and no clinical study. Partnering →

How was this landscape built, and how is AI hallucination avoided?

One search in AcademicLabs returned 4,264 CIDP records across eight types of intelligence: publications, patents, clinical studies, companies, research groups, researchers, funded projects and news. AcademicLabs AI analysed each record on its own against a fixed CIDP question set, using only that record's text: no web searches, and no facts from the model's training data, which is used for reasoning only. Counting, deduplication and cross-linking were then done in code, and a final step wrote up the insights and built the visuals. Method →

How current is this report?

The records were exported from AcademicLabs between 20 August and 30 September 2026. Readout dates are primary completion dates registered by the sponsors and often move. The report was published on 29 September 2026 and last updated on 7 October 2026, when registry duplicates were merged further and preclinical programmes were added. Method →

About this report

Prepared by Arne Smolders , Founder & CEO of AcademicLabs. Published 29 September 2026, updated 7 October 2026; data as of 30 September 2026. Built with AcademicLabs from 4,264 AI-analysed records across eight types of intelligence. Figures describe what the records state and are not medical or investment advice. Not yet covered: Chinese-language patents and pipeline charts on company websites, which come with AcademicLabs asset intelligence.

How to cite

Please cite and link this page:

METHOD (summary; the full method is on the page)

- Coverage: The report covers what AcademicLabs held on CIDP at the export dates: clinical trials from ClinicalTrials.gov, the EU registers and WHO ICTRP (which brings in the Chinese, Japanese, Australian, Dutch, Iranian and other national registries), publications, patents, companies, research groups,…

- Registry deduplication: Records were merged when they shared any registry identifier (NCT, EudraCT, CTIS, WHO), cited each other's NCT number, or had near-identical titles (similarity ≥ 0.92). Studies registered under different titles in several registries (a brief and a scientific title, a translated title, or an EudraCT…

- CIDP relevance: A study is CIDP-specific when CIDP is in its title or among three or fewer listed conditions, multi-indication when CIDP appears in conditions, summary or inclusion criteria, and off-target otherwise. 160 studies are CIDP-specific and 56 multi-indication.

- Asset resolution: Interventions were resolved against a dictionary of about 55 named products, codes and synonyms. Comparators, background therapy and lymphodepletion regimens are dropped when a novel agent is present. 138 of 216 relevant studies resolve to a named intervention; the rest test procedures, devices,…

- Developer evidence ladder: Marketed in CIDP requires a post-approval CIDP study of the developer's branded product or approval news. Active clinical requires being first-listed sponsor of an active interventional study of a resolved asset. Then completed studies, then patents or preclinical records, then literature or news…

- One mechanism axis: Publication mechanisms, patent targets, trial interventions and project themes were mapped to the same twelve mechanisms so they can be read across. Cell therapies and stem-cell transplantation count under B cells and plasma cells; immunoglobulin, being polyvalent, is left off the axis.